94 results about "Hypercholesteraemia" patented technology

Described are RNAi agents, compositions that include RNAi agents, and methods for dual inhibition of an Apolipoprotein C-III (APOC3) and Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene. The APOC3-PCSK9 RNAi agents disclosed herein inhibit the expression of an APOC3 and a PCSK9 gene. Pharmaceutical compositions that include one or more APOC3-PCSK9 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to hepatic cells, in vivo, provides for inhibition of APOC3 and / or PCSK9 gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including hypertriglyceridemia and hypercholesterolemia.

Increase of energy expenditure as an effective treatment of obesity and related disorders is a target for drug research and development. A 15% increase of energy expenditure is believed to be sufficient to achieve significant weight and fat mass reduction while providing meaningful improvement of metabolic parameters. Disclosed herein is a method for pharmacological inhibition of miR-22-3p, which represents a new therapeutic approach for treating human obesity, diabetes, and hypercholesterolemia.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

The invention relates to the technical field of microorganisms, and discloses an application of a secondary metabolite of phytobacterium plantarum YN-06 in lowering cholesterol, the phytobacterium plantarum YN-06 is preserved in China Center for Type Culture Collection, the preservation address is Wuhan University, Wuhan, China, the preservation time is March 13, 2025, the preservation number is CCTCC NO: M 2025471, and the classification name is Lactobacillus plantarum YN-06. According to the application of the secondary metabolite of the phytobacterium plantarum YN-06 in lowering cholesterol, the YN-06 has a remarkable cholesterol degradation effect, can produce various beneficial metabolites such as L-beta-homoserine and 5-amino valeraldehyde, can be used for developing fermented dairy products and other functional foods with a cholesterol lowering function, and has a wide application prospect. And new strategies and products are provided for preventing and improving hypercholesteremia and related cardiovascular diseases.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The invention discloses application of rhodotorula red in preparation of a product for effectively preventing / treating hypercholesteremia, and belongs to the technical field of dual purposes of medicine and food. The invention relates to an application of rhodotorula benthamiana in preparation of a product for effectively preventing / treating hypercholesteremia. The rhodotorula benthamiana is rhodotorula benthamiana electrostatic spinning microspheres. Compared with a rhodotorula red bile system, the rhodotorula red electrostatic spinning microsphere system has an obviously better intervention effect on hypercholesterolemia. Meanwhile, compared with a rhodotorula rubra bile system, the rhodotorula rubra electrostatic spinning microsphere system can effectively improve the serum and liver inflammatory factor level of a hypercholesteremia mouse and prevent excessive accumulation of liver lipid, especially ceramide lipid, of the hypercholesteremia mouse.

The present invention relates to a combination of Chinese and Western medicines for treating hyperlipidemia. In particular, the present invention relates to a pharmaceutical combination of probucol and red yeast rice, a pharmaceutical composition or a kit comprising probucol and red yeast rice, and the use of the pharmaceutical combination, pharmaceutical composition or kit in preparing a medicament for treating hyperlipidemia, particularly severe hypertriglyceridemia and severe hypercholesterolemia. The present invention is characterized in that the pharmaceutical combination, pharmaceutical composition or kit comprising probucol and red yeast rice comprises a small dose of probucol and red yeast rice, and the probucol and red yeast rice are configured for simultaneous administration.

Compositions and method of increasing levels of apoA1 and / HDL in a subject in need thereof are provided. The compositions include one or more TLR5 agonists in a pharmaceutically acceptable carrier in an effective amount to increase the level of apoA1 and / or HDL in a subject. In a preferred embodiment, the composition is an oral formulation of the one or more TLR5 agonists. The disclosed methods include administering compositions containing the one or more TLR5 agonists to a subject in need thereof, in an effective amount to increase levels of apoA1 and / or HDL in the subject. In one preferred embodiment, the subject is at risk of developing atherosclerosis and / or coronary heart disease. In some embodiments, the subject is diagnosed as having atherosclerosis. The disclosed compositions can also be administered to subjects presenting with hyperlipidemia or hypercholesterolemia.

The invention relates to double-stranded nucleic acid molecules that interfere with or inhibit G Protein-Coupled Receptor 146 (GPR146) gene expression. It further relates to therapeutic uses of such inhibition such as for the treatment of GPR146-mediated diseases, disorders or syndromes, such as hyperlipidaemia, hypercholesterolaemia, Heterozygous familial hypercholesterolaemia (HeFH), Homozygous familial hypercholesterolaemia (HoFH), autosomal recessive hypercholesterolaemia, atherosclerosis, and / or atherosclerotic cardiovascular disease.

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, for reducing cholesterol, in particular total cholesterol (TC) and low-density lipoprotein cholesterol (LDL cholesterol). The invention also relates to dapiglutide for treatment of hyperlipidaemia, in particular hypercholesterolaemia.

The present invention relates to methods of treating or preventing cholesterol-related diseases (such as hypercholesterolemia, hyperlipidemia or dyslipidemia) using antibodies against proprotein convertase subtilisin / kexin type 9 (PCSK9). Also described are formulations and methods of producing the formulations.

The invention discloses application of aspidopterys obcordata extract in preparation of a medicine for preventing and / or treating hyperlipidemia. Animal experiments prove that the aspidopterys obcordata diluted ethanol extract can reduce the indexes such as TC, HDL-C, LDL-C, HDL / TC, APOA, APOB, UREA, TP, GLB, ALB / GLB and the like in the blood of a hyperlipidemia model rat, can remarkably reduce the liver visceral organ coefficient and regenerate liver cells, can be used for treating hypercholesteremia in hyperlipidemia, and has a good clinical application prospect.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to at least the 5′ end of either the sense or antisense RNA part of the molecule wherein the double stranded inhibitory RNA targets genes associated with cardiovascular disease in the treatment hypercholesterolemia and diseases associated with hypercholesterolemia such as cardiovascular disease.

The invention relates to the technical field of biological medicine. The invention provides a PCSK9-targeted PROTAC oral drug as well as a preparation method and application thereof. The drug comprises the following structures: a PCSK9 binding peptide, an E3 ubiquitin ligase ligand, a cell penetrating peptide and a flexible linker. The medicine provided by the invention can be used for preparing products for treating lipid metabolism disorder diseases such as hypercholesteremia and atherosclerosis. In addition, the medicine disclosed by the invention can also be combined with statins to synergistically enhance the lipid-lowering curative effect.

The disclosure provides methods of treating heterozygous familial hypercholesterolemia (HeFH) and / or atherosclerotic cardiovascular disease (ASCVD), more particularly in subjects who require additional lowering of low-density lipoprotein cholesterol (LDL-C). The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising obicetrapib or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

The invention discloses a preparation method of torreya grandis gel candies with an effect of reducing total cholesterol. The invention belongs to the technical field of functional food, the Chinese torreya oil and the flaxseed oil have a synergistic effect, and after the Chinese torreya oil and the flaxseed oil are compounded, the blood fat metabolism can be effectively regulated, the total cholesterol level can be reduced, and the content of high-density lipoprotein cholesterol can be increased; the Chinese torreya oil is extracted through a low-temperature pressing process, the linseed oil is prepared through a cold pressing process, active components in the raw materials are reserved to the maximum extent, and meanwhile, the stability and uniformity of functional components in the product are ensured by combining a feeding pump filtering process and a rolling die shaping process; by optimizing the formula and the preparation process of the gel matrix, the product has good elasticity and chewing feeling, is convenient to carry and take and is suitable for daily use. The health-care food does not contain artificially synthesized additives, all the raw materials are natural sources, and the health-care food is suitable for patients with hypercholesterolemia and crowds needing to regulate blood fat, and has relatively high safety and market promotion value.

The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).

A hypercholesterolemic profile of a patient is determined on the basis of (i) a first statistical distribution based on a scale of polygenic risk score levels and a scale of cholesterol concentration levels in low-density lipoproteins, the first statistical distribution giving, based on these scales, a distribution of individuals in a first sub-sample of severely hypercholesterolemic individuals having at least one genetic mutation causing hypercholesterolemia for at least one gene from a set of genes and (ii) a second statistical distribution based on the same scale of polygenic risk score levels and the same scale of cholesterol concentration levels in low-density lipoproteins,the second statistical distribution giving, as a function of these scales, a distribution of individuals from a second sub-sample of severely hypercholesterolemic individuals not presenting a genetic mutation in the set of genes;

The invention relates to the technical field of treatment of metabolic syndromes, in particular to application of sennoside A in preparation of anti-metabolic syndrome drugs and / or health care products. It is found that the sennoside A can improve glycolipid metabolism of metabolic syndrome model mice induced by high fat diet, inhibit obesity and improve hypercholesterolemia and increase of low-density lipoprotein; the abnormities of fasting blood glucose, fasting insulin, fasting C peptide and plasma GLP-1 of metabolic syndrome model mice can be improved, and the insulin sensitivity of OGTT, ITT and HOMA-IR can be improved; in addition, abnormal expression of WT-HFD metabolic syndrome model mouse Sirt3 can be effectively relieved, GLP-1 protein expression can be promoted, and phosphorylation of IRS-1 / PI3K / AKT insulin signal transduction pathway key molecules is promoted; meanwhile, it is found that Sirt3 is a key molecule of sennoside A for exerting the treatment effect.

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

The invention relates to oral probiotic hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing inulin-modified thiolated polysaccharide with a probiotic liquid, and quickly crosslinking to form probiotic hydrogel, so as to construct a colon-targeted probiotic delivery system; the system can effectively protect the probiotics from passing through the upper digestive tract, and realizes targeted release of the probiotics at the colon part by using a dual mechanism that the inulin is specifically ingested by the probiotics in the colon and the disulfide bond is easily reduced and disassembled by reduced glutathione (GSH) in the colon. The oral probiotic hydrogel disclosed by the invention is applied to preparation of medicines for preventing and treating irritable bowel syndrome, diarrhea, constipation, dyspepsia, inflammatory bowel disease, colon cancer, diabetes mellitus, obesity and hypercholesteremia.

Aspects of the disclosure relate to compositions and methods for multiplexed gene silencing in a cell or subject. In some embodiments, the disclosure provides an isolated nucleic acid or an rAAV encoding a transgene comprising a RNA-guided nuclease (RGN) operably linked to a first promoter, and a second promoter operably linked to a multi guide-RNA (multi-gRNA) expression cassette encoding one or more gRNAs targeting a gene associated with hypercholesterolemia or dyslipidemia. In some embodiments, the disclosure provides methods of treating a subject having hypercholesterolemia or dyslipidemia by administering the compositions.

The invention relates to a Chinese and western medicine composition for treating hyperlipemia. The invention relates to a probucol and red yeast rice medicinal composition, in particular to a probucol and red yeast rice medicinal composition or a medicine box containing probucol and red yeast rice, and application of the medicinal composition, the medicinal composition or the medicine box in preparation of medicines for treating hyperlipidemia, in particular severe hypertriglyceridemia and severe hypercholesteremia. The pharmaceutical composition, the pharmaceutical composition containing probucol and red yeast rice or the kit containing probucol and red yeast rice contains a small dose of probucol and red yeast rice, and the probucol and red yeast rice are configured in a form of simultaneous administration.

The present disclosure relates to novel therapeutic compounds referred to as RNAi agents that reduce the expression of HMGCR receptors (expressed by the HMGCR gene), thereby reducing mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving modulation of HMGCR expression and function, such as diseases and disorders that are risk factors of ASCVD (e.g., dyslipidemia, such as hypercholesterolemia).

The present invention provides methods for treating patients suffering from hyperlipidemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.